key: cord-1035600-sb8hj550
authors: Li, Hongxin; Zhao, Yong; Zhou, Lin
title: Cutaneous manifestations in children with SARS‐CoV‐2 infection and/or COVID‐19: what do we know after 10 months under this pandemic?
date: 2021-09-16
journal: Int J Dermatol
DOI: 10.1111/ijd.15882
sha: 60f320b9520cb7e8e56515e21de14d34fec4c134
doc_id: 1035600
cord_uid: sb8hj550

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a global crisis. However, cutaneous manifestations in children with SARS‐CoV‐2 infection have received little attention. OBJECTIVE: Our study was aimed to present clinical and cutaneous manifestations of children with SARS‐CoV‐2 and to provide the basis for early diagnosis. METHODS: We analyzed the clinical data of COVID‐19 infected (CI) children worldwide from December 2019 to October 6, 2020, by using search terms “COVID‐19,” “SARS‐CoV‐2,” “Coronavirus” in combination with “cutaneous,” “lesion,” “rash,” “skin,” “dermatology,” “epidermis,” “dermis,” “multisystem inflammatory syndrome.” We collected and analyzed the general information, clinical symptoms, cutaneous manifestations, laboratory examination results, history of close contact with CI patients or suspected CI patients, and outcome in CI children. RESULTS: Among 90 CI children, there were 46 boys (59%) and 32 girls (41%). Erythema was the most frequent lesion, followed by conjunctivitis, and edematous lesions. Face was the most commonly affected location including lips, conjunctivae, tongue, eyes, and eyelids. Sixty‐three (73.3%) patients had multisystem inflammatory syndrome (MIS‐C). As for clinical symptoms, 70 (81.4%) CI children suffered fever, and 34 (39.5%) patients had lung involvement. Meanwhile, 65.1% of patients had cardiac involvement, 4.7% of patients were asymptomatic, and 71.6% of patients received intravenous immunoglobulin, as well as 31.1% of CI children received systemic corticosteroids. Three children were dead. The most frequent route of infection was familial clustering. As silent virus carriers of CI children, it is important to find out the clinical and cutaneous manifestations in CI children to prevent and control COVID‐19 transmission.

Coronavirus disease 2019 (COVID-19) has become a global pandemic crisis that causes severe respiratory tract infection. As of October 6, more than 36 million confirmed patients have been reported across 214 countries and territories resulting in more than 1 million deaths. With significantly increased morbidity, transmission route, pathogenesis, clinical manifestations, and prognosis of COVID-19 infection (CI) have attracted more and more attention.

The clinical spectrum of CI is extremely variable, ranging from asymptomatic to severe pneumonia and multiple organ failures. 1 Common symptoms include fever, dry cough, sore throat, headache, fatigue, abdominal pain, nausea, vomiting, anosmia, myalgia, dyspnea, acute respiratory distress syndrome (ARDS), sputum production, hemoptysis, and diarrhea. 2, 3 COVID-19 could be transmitted by asymptomatic and presymptomatic carriers. 4 Presymptomatic transmission is considered to be very important in COVID-19 transmission, with a rate of 48-62% in presymptomatic patients. 5 COVID-19 causes multisystemic infection including the skin.

The prevalence of cutaneous lesions with CI ranged from 0.2% to 20 .4% in different countries. 6, 7 Cutaneous manifestations are variable. Marzano divided the reported cutaneous lesions into six main clinical patterns: urticarial rash, confluent erythematousmaculopapular-morbilliform rash, papulovesicular exanthem, chilblain-like acral pattern, livedo reticularis-livedo racemosa-like pattern, and purpuric "vasculitic" pattern. 8 Right now, cutaneous manifestations get more and more attention from dermatologists.

Chilblain-like lesion was strongly associated with CI, especially in asymptomatic pediatric patients. 9 Maculopapular eruptions, urticaria, or acral vasculopathic rashes (pseudo-chilblains, perniolike lesions) considered as "COVID toe" are the most frequently mucocutaneous manifestations of CI. 10 COVID toes are very common in children as well as in adults in the range of 80-90 years old. 11 Chilblain-like lesion, ischemic lesion, and ecchymotic acral lesion could be found in asymptomatic or mildly symptomatic patients because of the coagulation disorder or hypersensitivity reaction, probably. 12 Rash occurred before other symptoms was in 77.9% CI patients. 13 Pediatric population is less likely to be affected by COVID-19 than adults. There were less than 3% of reported cases in patients under 20 years. 14 

We analyzed studies published in the PubMed database and in Chinese medical journal search engines such as Wanfang Data (http://www.wanfangdata.com.cn/), Science China (http://www. cnki.net/) from December 2019 to October 6, 2020. Search MeSH terms "COVID-19," "SARS-Coronavirus-2," and "Coronavirus" were used in combination with "cutaneous," "lesion," "rash," "skin,"

"dermatology," "epidermis," and "dermis." Studies written in In viral infection, exanthems usually occur as an immune hypersensitivity response to viral DNA or RNA. 23 Coronavirus infections may own the same origin as the other virus lesions. 24 In our previous study, the most common lesion was erythema, followed by urticarial lesions in CI patients. 13 suspected CI patients whose CI tests were negative. In a PCRnegative COVID-19 chilblain-like patient, SARS-CoV-2 spike protein was showed depositing in the cytoplasm of cutaneous dermal vessels and eccrine cells. The negative test might be swift response from the innate immune system or to an antibody response different from that of patients without this cutaneous presentation, 26 or because of the lower sensitivity of PCR for COVID-19 in mild cases or low viral load. 27 Locatelli presented a 10-year-old patient with a long-lasting chilblain-like lesion who went to the hospital and tested positive for COVID-19. 28 We suggest that suspected patients with negative initial test should be followed up for a long time, and pathological examination should be performed if necessary.

CI in children is commonly mild, possibly because of young age and lack of additional pathologies. 29 In our previous study, the trunk was the most affected location in CI patients. 13 In CI 33, 34 In our study, the youngest CI child was 2 months old. Most CI children were ranged from age 6 to 12 years old. It is believed that COVID-19 is a low risk for vertical transmission. Some researchers found better neonatal outcomes and no maternal deaths when mother were infected in the third trimester of pregnancy. 35, 36 However, SARS-CoV-2 RNA was also found on the fetal side of the placenta in CI mothers, and neonates were positive for virtue at birth. 37 Baud presented placental and amniotic membranes which tested positive for SARS-CoV-2 in a miscarriage CI woman during the second trimester. 38 "Kawasaki-like" syndrome was first published in April 2020 and then reported in Spain, Italy, and the USA. 39 On May 14, 2020, this syndrome was named "Multisystem Inflammatory Syndrome in Children (MIS-C)," which probably affected children beyond infancy. CI children with multisystem inflammatory syndrome share many similarities with Kawasaki disease (KD), 40 presenting with persistent fever, asthenia, rash, conjunctivitis, oral mucosa changes, redness of oropharynx, hands or feet edema, cardiac involvement, gastrointestinal symptoms, symptoms of shock, and even death. 41 However, MIS-C differentiates from KD, 41 which has a similar clinical presentation to

Kawasaki disease, toxic shock syndrome, and severe sepsis. 42 The morbidity of MIS-C was 0.6% in CI children. 43 There was a 30-fold increase in Kawasaki-like disease after COVID-19 epidemics. We found many countries reported MIS-C, including which might be a genetic factor. 46 Marie found CI children who presented with severe KD-like syndrome had a high risk of poor outcome for patients more than 5 years old and had a high level of ferritin. 47 50 Respiratory, gastrointestinal, and neurological symptoms and cardiovascular involvement commonly present in MIS-C patients. 44 In our study, 68.6% of patients had diarrhea, vomiting, and abdominal pain. Acute renal injury was found in 11.9% of children. 51 We also found 54 CI children increased the possibility of fecal-oral transmission through persistent shedding of COVID-19 in stools. 55 Cutaneous lesions vary at different times in the disease course and associate with different duration, severity, and prognosis. 56 In our study, 78.9% of patients had other symptoms before cutaneous lesions.

In our review, 4.7% of CI children were asymptomatic. Esther found 22% of adult CI patients with pernio-like lesions were asymptomatic. The asymptomatic or paucisymptomatic COVID-19 children may not go to the hospital or take examinations. We also found that many suspected children had negative tests. It may be because of lower sensitivity of PCR for COVID-19 in mild cases or low viral load. 27 In order to reduce the spread of COVID-19 virus, rashes and clinical manifestations of suspected children should also be of great concern to doctors.

Our review has many limitations. First, because of the few number of CI children, the sample size may result in bias. Second, CI had a mild influence in children. Most parents refused to take biopsy examination. We still have unclear cutaneous histopathology manifestations of CI children.

In summary, the contribution of children to the asymptomatic transmission of COVID-19 should be emphasized because of the impact on control measures for identification, isolation of children, and for tracing close contacts as well. Cutaneous manifestations on CI children are still concerning. Whether CI has a long-term or short-term impact on children is still unknown.

Cutaneous manifestations and pathological studies in CI children can be a useful clue to diagnose and predict disease outcomes in CI children. We suggest more attention should be paid to asymptomatic or mild symptoms in children, who could help us with early detection of silent carriers. COVID-19 virus has mutated globally. CI rashes are of great significance for early diagnosis.

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial

Presumed asymptomatic carrier transmission of COVID-19

Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data

Clinical characteristics of coronavirus disease 2019 in China

Cutaneous manifestations in COVID-19: a first perspective

Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue

Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series

Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak

Cutaneous, skin histopathological manifestations and relationship to COVID-19 infection patients

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

SARS-CoV-2 (COVID-19): what do we know about children? A systematic review

Epidemiology of COVID-19 among children in China

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Virological assessment of hospitalized patients with COVID-2019

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

High expression of ACE2 on keratinocytes reveals skin as a potential target for SARS-CoV-2

COVID-19: how it can look on the skin. Clinical and pathological features in 20 COVID-19 patients observed in Bologna, north-eastern Italy

Viral exanthems: an update on laboratory testing of the adult patient

Cutaneous manifestations in COVID-19: a first perspective

COVID-19 and cutaneous manifestations: a systematic review

COVID-19 chilblainlike lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a PCR-negative patient

Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid

Histologic features of long-lasting chilblain-like lesions in a paediatric COVID-19 patient

Dertlio glu SB Skin manifestations in COVID-19: A case series of five patients from Elazı g, Turkey. Dermatologic Therapy

A viral rash: the impact of COVID-19 infection on the skin

Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries

Cutaneous manifestations of SARS-CoV-2 infection: a clinical update

Major cluster of paediatric 'true' primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown

Evaluation of chilblains as a manifestation of the COVID-19 pandemic

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China

Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth

Second-trimester miscarriage in a pregnant woman with SARS-CoV-2 infection

COVID-19 and Kawasaki disease: novel virus and novel case

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children

Hyperinflammatory shock in children during COVID-19 pandemic

Multisystem inflammatory syndrome in children in New York State

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Immunologic features in coronavirus disease 2019: functional exhaustion of T cells and cytokine storm

Covid-19 and Kawasaki syndrome

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Antibody responses to SARS-CoV-2 in patients with COVID-19

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki disease cases

The natural history of SARS-Cov-2 related multisystem inflammatory syndrome in children (MIS-C): a systematic review

Histologic features of long-lasting chilblain-like lesions in a paediatric COVID-19 patient

Erythema multiformelike lesions in children and COVID-19

Environment and personal protective equipment tests for SARS-CoV-2 in the isolation room of an infant with infection

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Cutaneous manifestations of SARS-CoV-2 infection: a clinical update